📋 Key Information Summary
- Definition: Barrett's oesophagus (BO) is the replacement of normal squamous epithelium of the distal oesophagus by columnar intestinal metaplasia (IM) confirmed on biopsy, predisposing to oesophageal adenocarcinoma (OAC).
- Prague C&M classification documents circumferential (C) and maximum (M) extent of visible columnar-lined oesophagus; standardises reporting and surveillance planning.
- Surveillance: Seattle protocol 4-quadrant biopsies every 1–2 cm of the Barrett's segment; chromoendoscopy or virtual chromoendoscopy adjunctive to white-light endoscopy recommended.
- Surveillance intervals are stratified by segment length and dysplasia grade — no dysplasia 3–5 years, low-grade dysplasia (LGD) 6–12 months, high-grade dysplasia (HGD) 3 months or proceed to endoscopic eradication therapy (EET).
- Dysplasia confirmation by a second expert gastrointestinal pathologist is mandatory before any treatment decision for LGD or HGD.
- Endoscopic eradication therapy is the standard of care for HGD and intramucosal carcinoma; radiofrequency ablation (RFA) is first-line for flat dysplasia, endoscopic mucosal resection (EMR) for visible lesions.
- EMR is both diagnostic (staging) and therapeutic for nodular or mucosal irregularities; endoscopic submucosal dissection (ESD) offers higher en-bloc resection rates for selected larger lesions.
- Post-ablation surveillance is essential even after complete eradication of intestinal metaplasia (CE-IM), as buried metaplasia and recurrence can occur.
- High-dose PPI therapy (e.g., esomeprazole 40 mg BD) is the cornerstone of acid suppression; combined with lifestyle modifications — weight loss, head-of-bed elevation, smoking cessation, alcohol reduction.
- Aspirin chemoprevention: The AspECT trial demonstrated that high-dose PPI combined with aspirin reduces the risk of progression to HGD/OAC; aspirin 300 mg/day is the studied dose (consider cardiovascular risk).
- Screening indications: Male sex, age >50, chronic GORD >5 years, central obesity, Caucasian ethnicity, smoking, family history of BO or OAC; BSG and ACG recommend screening endoscopy in at-risk populations.
- Cytosponge-TFF3 is a non-endoscopic cell collection device under evaluation for primary care triage; not yet standard of care in Australia but trialled in selected centres.
- Oesophageal adenocarcinoma risk in BO is approximately 0.3% per year; progression rates are LGD → HGD/OAC ~0.5–1%/year, HGD → OAC ~6–7%/year without treatment.
- ATSI considerations: BO and OAC are less prevalent in Aboriginal and Torres Strait Islander peoples, but delayed access to endoscopy services in remote areas may lead to later-stage presentation; culturally safe screening pathways are essential.
Diagnosis & Surveillance
Endoscopic Biopsy Diagnosis & Intestinal Metaplasia
Diagnosis of Barrett's oesophagus requires both endoscopic evidence of columnar-lined oesophagus (CLO) extending above the gastro-oesophageal junction (GOJ) and histological confirmation of intestinal metaplasia (IM) with goblet cells on biopsy. The presence of IM is considered the hallmark for diagnosis in Australia, consistent with BSG and ACG guidelines. Cardiac-type mucosa without goblet cells does not constitute Barrett's oesophagus.
At index endoscopy, the endoscopist must:
- Document the Z-line (squamocolumnar junction) relative to the diaphragmatic hiatus and GOJ.
- Describe the presence and extent of visible columnar epithelium in the oesophagus.
- Take biopsies using the Seattle protocol — 4-quadrant biopsies every 1–2 cm from the Barrett's segment (above the GOJ to the squamocolumnar junction).
- Specify any visible lesions (nodularity, ulceration) and resect these with EMR before random biopsies.
Critical: Visible lesions or mucosal irregularities within a Barrett's segment must be resected by EMR first (not random biopsied) to provide accurate histological staging, as endoscopic appearance alone cannot reliably distinguish LGD from HGD or early OAC.
Prague C&M Classification
The Prague C&M classification is the international standard for documenting Barrett's extent:
| Parameter | Definition | Clinical Significance |
|---|---|---|
| C (Circumferential) | Maximum length of circumferential Barrett's epithelium (in cm) from the GOJ | Determines surveillance interval and treatment planning |
| M (Maximum) | Maximum extent of any Barrett's epithelium (tongues or islands) from the GOJ | M ≥ C always; M < 1 cm is not reliably classifiable |
| Short-segment | C < 3 cm | Lower cancer risk but still requires surveillance |
| Long-segment | C ≥ 3 cm | Higher risk of dysplasia and OAC |
Seattle Protocol Biopsies
The Seattle protocol (systematic 4-quadrant biopsies every 1–2 cm) remains the gold standard for dysplasia detection in Barrett's surveillance. Random biopsies improve dysplasia detection yield compared with targeted biopsies alone.
Adjunctive technologies:
- Chromoendoscopy: Acetic acid or methylene blue spraying improves mucosal pattern recognition and targeted biopsy yield.
- Virtual chromoendoscopy: Narrow-band imaging (NBI, Olympus), i-SCAN (Pentax), or blue-light imaging (BLI, Fujifilm) enhance mucosal and vascular pattern assessment.
- Volumetric laser endomicroscopy (VLE) and confocal laser endomicroscopy are available in select tertiary centres.
Surveillance Intervals
| Histological Finding | Surveillance Interval | Notes |
|---|---|---|
| No dysplasia, C < 3 cm | Every 5 years | At least two consecutive negative endoscopies before extending interval |
| No dysplasia, C ≥ 3 cm | Every 3 years | Higher risk segment warrants more frequent surveillance |
| Indefinite for dysplasia | Repeat at 6–12 months with optimised PPI | Ensure adequate acid suppression and quality biopsies before resurvey |
| Low-grade dysplasia (confirmed) | Every 6–12 months | EET recommended — refer to Dysplasia Management section |
| High-grade dysplasia (confirmed) | Every 3 months or proceed to EET | Endoscopic eradication therapy is strongly preferred over surveillance |
Safety alert: Surveillance endoscopy must be performed by an experienced endoscopist using high-definition white-light endoscopy with virtual or dye-based chromoendoscopy. A negative surveillance endoscopy that misses dysplasia due to inadequate technique (e.g., suboptimal insufflation, poor mucosal cleansing, insufficient biopsy sampling) constitutes a significant patient safety concern.
Dysplasia Management
Confirmation by Second Expert GI Pathologist
Before any treatment decision for dysplasia in Barrett's oesophagus, histological confirmation by a second expert gastrointestinal pathologist is mandatory. This is particularly important for low-grade dysplasia (LGD), which has the highest inter-observer variability among pathologists.
Key principle: Up to 60% of community diagnoses of LGD are downgraded to indefinite for dysplasia or no dysplasia on expert pathological review. Conversely, a proportion of LGD cases are upgraded to HGD. Expert pathology review is therefore essential and should be arranged through a multidisciplinary team (MDT) meeting before definitive management.
Classification of Dysplasia
| Grade | Histological Features | Estimated Progression Rate | Management Approach |
|---|---|---|---|
| Indefinite for dysplasia | Architectural and cytological atypia insufficient to diagnose dysplasia; often related to active inflammation/regeneration | Variable (treat active inflammation first) | Optimise PPI therapy; rebiopsy in 6–12 months |
| Low-grade dysplasia (LGD) | Nuclear stratification, hyperchromasia, mucin depletion confined to the basal half of the epithelium; no surface involvement | ~0.5–1.0% per year (up to 13% if confirmed by expert pathologist) | EET recommended (RFA preferred); continued surveillance if EET not feasible |
| High-grade dysplasia (HGD) | Full-thickness nuclear stratification, complex budding, cribriform architecture, surface maturation absent | ~6–7% per year | EET strongly recommended; RFA ± EMR for visible lesions |
| Intramucosal carcinoma (IMC / T1a) | Malignant cells invading through the basement membrane into the lamina propria or muscularis mucosae | Risk of lymph node metastasis ~1–2% if well-differentiated, no lymphovascular invasion | EMR preferred for staging; EET curative if SM1 or less with favourable histology |
Indications for Endoscopic Eradication Therapy
- Confirmed HGD — EET is the treatment of choice (strong recommendation).
- Confirmed LGD — EET is recommended, particularly when confirmed by expert GI pathologist (moderate recommendation).
- Intramucosal carcinoma (T1a) — EET is curative in the absence of lymphovascular invasion, poorly differentiated histology, or deeper submucosal invasion (>SM1).
- T1b (submucosal invasion <SM1, favourable histology) — EET may be considered if performed at a high-volume centre with endoscopic and surgical expertise; discussion at upper GI MDT mandatory.
Repeat Mapping Biopsies
Prior to commencing EET, repeat mapping biopsies using the Seattle protocol should be performed if the most recent surveillance endoscopy was >3 months prior. This ensures accurate assessment of the extent of dysplasia and excludes synchronous lesions that may alter the treatment plan.
All visible lesions should be resected (EMR preferred) and submitted separately for histological staging. Random 4-quadrant biopsies every 1 cm should also be obtained from the remaining flat Barrett's segment.
Endoscopic Therapy
Endoscopic eradication therapy (EET) is the standard of care for dysplastic Barrett's oesophagus. EET comprises endoscopic resection of visible lesions followed by ablative therapy of the remaining flat Barrett's segment to achieve complete eradication of intestinal metaplasia (CE-IM) and dysplasia (CE-D).
Treatment paradigm: Resect first (EMR for visible lesions), then ablate the remainder (RFA). This combined approach achieves CE-IM rates of 85–95% and CE-D rates of 90–98% in expert centres.
Endoscopic Mucosal Resection (EMR)
EMR is both a diagnostic (staging) and therapeutic modality. It provides the most accurate histological assessment of mucosal neoplasia depth and is indicated for all visible lesions within a Barrett's segment.
- Ligation-assisted EMR (Duette™/Captivator™): Suck-and-cut technique; preferred for lesions ≤ 20 mm; lower perforation risk.
- Injection-assisted EMR: Submucosal injection of saline ± dye followed by snare resection; suitable for larger lesions.
- Cap-assisted EMR: Transparent cap fitted to endoscope tip with snare pre-looped; effective for flat lesions.
- En-bloc resection is feasible for lesions ≤ 15–20 mm; piecemeal resection acceptable for larger lesions (reduces pathological staging accuracy).
- Adverse events: bleeding 5–10%, perforation <1%, stricture 5–10% (higher with circumferential resection > 50% of circumference).
Radiofrequency Ablation (RFA)
RFA is the first-line ablative modality for flat (non-nodular) dysplastic Barrett's oesophagus. The HALO system (Covidien/Medtronic) delivers controlled radiofrequency energy to ablate the Barrett's epithelium.
HALO90 RFA (circumferential or focal)
Covidien / Medtronic · Ablation catheter
Technique
HALO360 balloon for circumferential segments; HALO90 endoscopic catheter for focal/tongue areas
Dosing
12 J/cm² twice per treatment session; repeat every 2–3 months until CE-IM achieved
Typical sessions
2–4 sessions for complete eradication
CE-IM rate
85–95% in randomised controlled trials
Stricture rate
5–6% (higher if prior EMR of > 50% circumference)
Endoscopic Submucosal Dissection (ESD)
ESD enables en-bloc resection of larger mucosal lesions (≥ 20 mm) that are not amenable to en-bloc EMR. It provides superior histopathological specimens for accurate staging of invasion depth.
- Indicated for: lesions ≥ 20 mm where en-bloc EMR is not feasible; suspected submucosal invasion; lesions at high risk of submucosal fibrosis (post-biopsy or prior ablation).
- En-bloc resection rate: >90% in expert hands.
- Higher perforation risk (4–6%) compared with EMR; should be performed only by experienced interventional endoscopists.
- Stricture rate: 10–20% (similar to EMR); prophylactic steroid therapy may reduce risk.
- Availability in Australia: limited to major tertiary centres (selected hospitals in Sydney, Melbourne, Brisbane, Adelaide, Perth).
Cryotherapy
Cryotherapy (cryoablation) is an alternative ablative modality using liquid nitrogen or CO₂ spray to induce cellular destruction. It is considered second-line therapy when RFA is not feasible or has failed.
- Available systems: CryoBalloon (C2 Therapeutics/Pentax), liquid nitrogen spray (CSA Medical).
- Typically applied in 2–3 freeze-thaw cycles per treatment session; repeat every 6–8 weeks.
- CE-IM rates: 60–80% in refractory cases; lower quality evidence compared with RFA.
- May be useful for treatment of buried Barrett's (subsquamous intestinal metaplasia) after prior RFA.
- Availability in Australia: limited to select tertiary centres.
Post-Ablation Surveillance
Ongoing surveillance is essential even after complete eradication of intestinal metaplasia (CE-IM). Buried Barrett's glands (subsquamous intestinal metaplasia), recurrence of visible Barrett's, and metachronous neoplasia can occur.
| Post-EET Status | Surveillance Interval | Biopsy Protocol |
|---|---|---|
| CE-IM achieved (no dysplasia) | Year 1, 2, 3, then every 3 years | 4-quadrant biopsies from neo-Z-line and below (every 1 cm of original Barrett's length) |
| CE-D but residual non-dysplastic IM | Every 12 months until CE-IM, then standard surveillance | Continue ablation attempts + Seattle protocol biopsies |
| Recurrent dysplasia post-EET | Repeat EET; refer to tertiary centre if refractory | Resect visible lesions (EMR) then re-ablate; consider ESD or cryotherapy |
Medical & Lifestyle Management
High-Dose PPI Therapy
Proton pump inhibitor (PPI) therapy is the cornerstone of acid suppression in Barrett's oesophagus. High-dose PPI is recommended for all patients with BO, including those undergoing surveillance and post-EET.
Esomeprazole
Nexium® · Generic · Proton pump inhibitor
Adult dose
40 mg PO BD (high-dose) or 20–40 mg PO OD (standard maintenance)
Renal adjustment
No dose adjustment required (eGFR < 30: use with caution)
Hepatic adjustment
Severe hepatic impairment: max 20 mg/day
PBS status
✔ PBS General Benefit
Pantoprazole
Somac® · Generic · Proton pump inhibitor
Adult dose
40 mg PO OD–BD
Renal adjustment
No dose adjustment required
PBS status
✔ PBS General Benefit
The AspECT trial (Aspirin and Esomeprazole Chemoprevention in Barrett's; Lancet 2018) demonstrated that high-dose esomeprazole (40 mg BD) reduced the risk of progression to HGD, OAC, or death by approximately 20% compared with low-dose PPI. The combination of high-dose PPI + aspirin provided the greatest risk reduction (~40%).
Aspirin Chemoprevention
Aspirin
Aspro Clear® · Cartia® · Generic · Antiplatelet / NSAID
Adult dose (chemoprevention)
300 mg PO OD (AspECT trial dose)
Considerations
Weigh GI bleeding risk vs cardiovascular benefit; lowest effective dose (75–100 mg) if also indicated for CVD prevention
PBS status
✔ PBS General Benefit
The NNT for aspirin chemoprevention in BO is approximately 25–30 over 8 years. Discussion with patients about the balance of benefit (reduced cancer risk) and harm (GI bleeding, bruising) is essential. Aspirin should be considered in patients with BO who have additional cardiovascular risk factors.
Lifestyle Modifications
Lifestyle
Weight Loss
Central obesity (increased waist circumference, BMI > 30) is the strongest modifiable risk factor for BO progression. Target BMI < 25 kg/m²; even modest weight loss (5–10%) reduces intragastric pressure and reflux episodes.
Setting: GP, dietitian referral
Lifestyle
Head-of-Bed Elevation
Elevate the head of the bed by 15–20 cm using bed blocks or a wedge pillow. Reduces nocturnal acid exposure and improves symptom control. Avoid merely using extra pillows (promotes flexion, not gravitational drainage).
Setting: Patient self-management
Lifestyle
Smoking Cessation
Current smoking doubles the risk of OAC in patients with BO. Smoking cessation should be strongly encouraged at every consultation. Refer to Quitline (13 7848) and consider nicotine replacement therapy or varenicline (Champix®).
Setting: GP, Quitline, pharmacy
- Alcohol reduction: Limit to ≤ 2 standard drinks/day; heavy alcohol use increases GORD and OAC risk.
- Dietary modifications: Avoid late-night eating (allow ≥ 3 hours before recumbency); reduce fatty, spicy, and acidic foods if symptomatic; smaller, more frequent meals.
- Avoid precipitating medications: Calcium channel blockers, nitrates, benzodiazepines, anticholinergics, and NSAIDs (other than aspirin for chemoprevention) may worsen reflux via lower oesophageal sphincter relaxation.
Screening & Risk Factors
Risk Factors for Barrett's Oesophagus
| Risk Factor | Relative Risk / Odds Ratio | Strength of Evidence |
|---|---|---|
| Male sex | OR 2.0–3.0 | Strong (consistent across studies) |
| Age > 50 years | OR 2.0–4.0 | Strong |
| Chronic GORD > 5 years | OR 3.0–6.0 | Strong |
| Central obesity (waist circumference) | OR 1.5–2.5 per 10 cm increase | Strong |
| Current smoking | OR 1.5–2.0 | Strong |
| Caucasian ethnicity | Higher prevalence than Asian, African, or Indigenous populations | Moderate |
| Family history of BO or OAC (first-degree relative) | OR 2.0–4.0 | Moderate |
| Hiatal hernia | OR 2.0–3.5 | Moderate |
Screening Recommendations
There is no national population-based screening programme for Barrett's oesophagus in Australia. The following recommendations are based on BSG (2014), ACG (2022), and AGA guidelines, adapted for the Australian context:
1
Who Should Be Screened?
Consider one-off screening endoscopy in patients with chronic GORD symptoms (> 5 years) AND multiple risk factors (male sex, age > 50, central obesity, family history). Routine screening in women or individuals without GORD is not recommended.
2
Screening Modality
High-definition white-light oesophagogastroduodenoscopy (OGD) with systematic biopsies is the gold standard. Sedation rates in Australia are high (> 95%); propofol sedation is available in major centres.
3
Cytosponge-TFF3
A swallowable capsule-sponge device that collects oesophageal cells for TFF3 immunostaining. The BEST3 trial (Lancet 2020) demonstrated 10-fold increased detection of BO vs usual care. Not yet PBS-listed in Australia; available in select research trials. May serve as a triage tool to reduce unnecessary endoscopies in primary care.
4
Family Screening
First-degree relatives of patients with BO or OAC have a significantly increased risk. Consider screening endoscopy in first-degree relatives with GORD symptoms, especially if the index case had OAC.
Australian context: In Australia, endoscopy services are predominantly delivered through public hospital endoscopy units and private gastroenterology practices. Wait times for non-urgent OGD can extend to 3–6 months in the public system. GP-initiated referral pathways and risk-stratification tools (e.g., Cytosponge, risk scores) may help prioritise patients most likely to benefit from screening.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
📚 References
- 1. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's oesophagus. Gastroenterology. 2011;140(6):1084-1091.
- 2. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: Diagnosis and Management of Barrett's Oesophagus. Am J Gastroenterol. 2016;111(1):30-50.
- 3. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63(1):7-42.
- 4. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's oesophagus: the Prague C&M criteria. Gastroenterology. 2006;131(5):1392-1399.
- 5. Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392(10145):400-408.
- 6. Phoa KN, van Vilsteren FGI, Weusten BLAM, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett's oesophagus and low-grade dysplasia (SURF trial): a multicentre, randomised controlled trial. JAMA. 2014;311(12):1209-1217.
- 7. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's oesophagus with dysplasia. N Engl J Med. 2009;360(22):2277-2288.
- 8. Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47(7):436-444.
- 9. Kadri SR, Lao-Sirieix P, O'Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.
- 10. Lao-Sirieix P, Boussioutas A, Kadri SR, et al. Non-endoscopic screening for Barrett's oesophagus (BEST3): a pragmatic randomised controlled trial in primary care. Lancet. 2020;395(10221):334-344.
- 11. Pohl H, Pech O, Arber H, et al. Endoscopy in Barrett's oesophagus: results of a population-based study. Gastrointest Endosc. 2013;77(5):725-733.
- 12. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase. International Agency for Research on Cancer; 2013.
- 13. Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2024. Canberra: AIHW; 2024.
- 14. National Health and Medical Research Council (NHMRC). Staying Healthy: Preventing Infectious Diseases in Early Childhood Education and Care Services. 5th ed. Canberra: NHMRC; 2012. (Adapted framework for chronic disease screening in primary care.)